Max Healthcare Institute Limited has announced that its Chairman and Managing Director will participate in an upcoming investor conference. The disclosure was made to the stock exchanges in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The executive is scheduled to attend the UBS Asian Investment Conference 2026 (AIC 2026). The conference is set to take place over two days, providing a platform for engagement with investors.

Conference Details

The meeting will be conducted in a physical format, allowing for both one-on-one and group interactions. The schedule for the event is outlined below:

Disclosure Notes

The company noted that the schedule remains subject to changes due to exigencies on the part of the investors or the company. Furthermore, Max Healthcare Institute Limited stated that no unpublished price sensitive information is proposed to be shared during the aforesaid investor conference. This information has also been hosted on the company's official website.

Max Healthcare Institute announced that the Competition Commission of India (CCI) has dismissed allegations of abuse of dominant position against its network hospitals. The regulatory body passed separate orders on May 21, 2026, in favour of the company, effectively closing the long-standing proceedings.

The development follows earlier intimations from the company dated August 14, 2023, and March 14, 2025. The case originated from an order dated August 31, 2018, wherein the CCI had directed the Director General (DG) to investigate the healthcare industry regarding the pricing of medicines, packages, and consumables provided by respondent hospitals in Delhi, which included six Max network hospitals.

Regulatory Proceedings and Findings

After the DG submitted its report, the findings were challenged by the respondent hospitals. The CCI subsequently considered a supplementary investigation report filed by the DG, along with the hospitals' objections, oral arguments, and written submissions. Upon review, the Commission rejected the DG's findings related to the alleged abuse of dominance.

The Commission concluded that no case of abuse of dominant position under Section 4 of the Competition Act, 2002, was established against the hospitals. The orders were received by the company on May 21, 2026, at 9:47 PM IST.

Status of Proceedings

The closure of these matters brings a resolution to the regulatory scrutiny faced by the network hospitals. The CCI's decision confirms that the pricing practices investigated did not violate competition laws. The detailed orders are available on the official website of the CCI.